Funding Opportunities

We offer funding for Alzheimer's drug discovery and preclinical development, clinical trials, and biomarker development research. Visit our Research Priorities for specific information about our interests.

Our funding is open to:
• Researchers, clinicians, and postdoctoral fellows
• Working in academia and biotechnology companies
• Based in the U.S. and worldwide

The ADDF currently accepts grant proposals through five RFPs. (For returning grantees, we accept proposals for follow-on funding and renewals.)


Preclinical Drug Discovery RFP

Purpose:

Seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to Alzheimer's disease, related dementias and cognitive aging.

Avg. Duration:

1-2 years

Avg. Award:

$150,000-$600,000

Next Deadlines: (4/year)

Letter of Intent: March 4, 2016
Invited Full Proposal: March 18, 2016

Review RFP (PDF)


Program to Accelerate Clinical Trials (PACT)

Purpose:

Designed to increase the number of novel and repurposed treatments tested in humans for Alzheimer's disease, related dementias and cognitive aging. It funds biomarker-based, proof-of-concept pilot clinical trials for Alzheimer's, as well as Phase 1 safety testing and IND-enabling studies to accelerate new drugs into trials.

Avg. Duration:

Varies

Avg. Award:

Up to $3 million

Next Deadlines: (4/year)

Letter of Intent: March 4, 2016
Invited Full Proposal: March 18, 2016

Review RFP (PDF)


ADDF/Belfer ApoE Therapeutics Innovation Program

Purpose:

Established to accelerate the development of novel therapeutics specifically designed to target apoE pathological mechanisms.

Avg. Duration:

Preclinical: 1-2 years
Clinical: varies

Avg. Award:

Preclinical: $150,000-$300,000
Clinical: up to $1.5 million

Next Deadlines: (4/year)

Letter of Intent: March 4, 2016
Invited Full Proposal: March 18, 2016

Review RFP (PDF)


Accelerating Drug Discovery for Frontotemporal Degeneration RFP

Purpose:

Accelerates drug discovery programs and biomarker development for frontotemporal degeneration and is funded in partnership with The Association for Frontotemporal Degeneration (AFTD).

Avg. Duration:

1 year

Avg. Award:

$100,000-$200,000

Next Deadline: (1/year)

September 2016

Next RFP available soon


ADDF/NIH RFP

Purpose:

The RFP supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.

Avg. Duration:

1-2 years

Avg. Award:

Varies

Next Deadline: (Rolling)

Proposals accepted on a rolling basis

Review RFP (PDF)


Apply for Funding

Print
Go to top